Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
Abstract Background The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer. Methods In this study, we util...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2021-07-01
|
| Schriftenreihe: | Breast Cancer Research |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s13058-021-01453-4 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|